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ABSTRACT
Here we provide the first strategy to use a compet-
itive Extendable Blocking Probe (ExBP) for allele-
specific priming with superior selectivity at the stage
of reverse transcription. In order to analyze highly
similar RNA variants, a reverse-transcriptase primer
whose sequence matches a specific variant selec-
tively primes only that variant, whereas mismatch
priming to the alternative variant is suppressed by
virtue of hybridization and subsequent extension of
the perfectly matched ExBP on that alternative vari-
ant template to form a cDNA–RNA hybrid. This hybrid
will render the alternative RNA template unavailable
for mismatch priming initiated by the specific primer
in a hot-start protocol of reverse transcription when
the temperature decreases to a level where such mis-
match priming could occur. The ExBP-based reverse
transcription assay detected BRAF and KRAS muta-
tions in at least 1000-fold excess of wild-type RNA
and detection was linear over a 4-log dynamic range.
This novel strategy not only reveals the presence or
absence of rare mutations with an exceptionally high
selectivity, but also provides a convenient tool for
accurate determination of RNA variants in different
settings, such as quantification of allele-specific ex-
pression.
INTRODUCTION
Single nucleotide polymorphisms (SNPs) and point mu-
tations are the most common types of genetic polymor-
phism (1), and they have been widely exploited as impor-
tant markers in diverse biomedical applications (2). Allele-
specific polymerase chain reaction (AS-PCR) and modifi-
cations thereof, which are based on the inability of a DNA
polymerase to extend a mismatched primer, have been pop-
ular in detection of single-nucleotide variants due to their
robustness and simplicity (3–24). However, AS-PCR usu-
ally has a modest selectivity due to considerable cross am-
plification. Although a better selectivity can be achieved in
certain mutation detection assays, it appears to be depen-
dent on the local sequence and the type of polymorphism
(25), and thus cannot be generalized to different mutation
detection assays. Furthermore, analysis of RNA variants by
AS-PCR and existing technologies requires, at the begin-
ning of the procedure, an additional step to non-specifically
convert RNA into cDNAprior toDNA-basedmutation de-
tection (26–28), which typically involves the steps of target
DNA amplification, an allele discrimination reaction and
detection of allele-specific products (29).
In contrast to AS-PCR, allele-specific priming during re-
verse transcription would in principle allow for direct trans-
formation of highly similar RNA variants into distinguish-
able allele-specific products in a single step, therefore, it has
long been expected to be a promising alternative for analysis
ofRNAvariants.However, pioneering investigators showed
that reverse transcriptases could initiate primer extension
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from a mismatched primer with sufficiently high efficiency
(30,31), leading to significant level of mismatch priming.
Due to this obstacle, allele-specific priming during reverse
transcription has until recently been unattainable with ap-
propriate selectivity. A few approaches have been described
for reducingmismatch-priming during reverse transcription
by using ‘non-extendable’ competitive blocking probes, but
such approaches have still suffered from a fairly low selec-
tivity (32), which restricts their broad usefulness in different
settings.
In this report, we describe the first strategy employing
an ‘extendable’ competitive blocking probe in reverse tran-
scription (ExBP-RT) to achieve allele-specific priming with
superior selectivity, which enables accurate detection and
quantification of RNA variants. In ExBP-RT strategy, the
mutated RNA template is selectively primed during re-
verse transcription by the mutation-specific primer, which
is coupled to a unique signature at its 5′ end to support
detection/discrimination of the allele-specific products in
the following step. Most importantly, mismatch priming to
themore abundant wild-typeRNA template is substantially
suppressed by the extendable wild-type-specific competitive
blocking probe using a hot-start protocol in reverse tran-
scription.
ExBP-RT is a simple, universal strategy for ultrasensitive
detection ofmutations inRNAsamples andmoreover, it en-
ables accurate determination of theRNA levels of expressed
mutations, which might reflect the functional consequences
brought upon the cells or tissues more faithfully than a
DNA-based mutation detection assay (33). This strategy
will offer a convenient research tool for epigenetic studies
to analyze allele-specific gene expression (34,35), RNA edit-
ing (36) as well as detection of RNA mutations within viral
RNAgenomes such asmutations conferring drug resistance
in HIV and influenza viruses (20,37).
MATERIALS AND METHODS
RNA samples
RNA templates used for assay development and validation
have been generated by in vitro transcription using DNA
templates with sequences corresponding to the wild-type
and different mutated variants of the KRAS and BRAF
genes. We prepared DNA templates for in vitro transcrip-
tion using PCR amplification of synthetic DNA oligonu-
cleotides, with forward and reverse primers targeting ‘un-
derlined’ sequences (Table 1). PCR amplification has been
performed with Phusion High-Fidelity DNA polymerase
(Finnzyme, Espoo, Finland, now part of Thermo Scientific)
and synthetic DNA oligonucleotides were obtained from
TAG Copenhagen A/S. Each oligonucleotide was about
100 nucleotides in length, including 20 nucleotides of T7
promoter’s sequence (in bold) at the 5′ end (Table 1).
The PCR products were used to synthesize RNAs by
in vitro transcription with AmpliScribeTM T7, T3 and SP6
High Yield Transcription Kits (Epicentre Biotechnologies)
according to manufacturer’s instruction. The concentra-
tions of resulting RNA samples were quantified using a
NanoVue spectrophotometer (GE Healthcare, Waskesha,
WI), and the copy numbers of the different RNA variants
were verified using quantitative RT-PCR (Tetro cDNA syn-
thesis kit and SensiFASTTM SYBR No-ROX Kit, Bioline).
The primers for these RT-PCR assays were obtained from
TAG Copenhagen A/S. The primer sequences are listed
in Table 2. The RNA samples corresponding to KRAS
and BRAF wild-type transcript sequences, as well as all
possible codon 12 KRAS variants and the BRAF V600E
(GTG>GAG) mutation were used for the assay develop-
ment and the determination of the selectivity of given as-
says.
Human RNA samples were extracted from formalin-
fixed paraffin embedded (FFPE) samples of colorectal can-
cer tumor tissue using phenol-chloroform extraction (38).
These samples were used as examples of utility of the ExBP-
RT assay. The use of clinical samples for this purpose was
approved by the institutional review board. All RNA sam-
ples were quantified with a NanoVue spectrophotometer
(GEHealthcare,Waskesha,WI) and diluted to 500 ng/l in
DEPC H2O, before the allele-specific reverse transcription
reaction.
ExBP-RT assay
For each analyzed mutation, a mutation-specific primer
was designed to target the mutant RNA and a wild-type-
specific blocking probe was designed to target the wild-type
RNA (Table 3). The mutation-specific primers included a
5′-prime tail that generated a priming site of non-related
sequence for the subsequent amplification reactions. Both
the mutation-specific primer and the blocking probe were
included in each reverse transcription reaction. All compo-
nents of the cDNA synthesis reactions except the enzyme
reverse transcriptase (Tetro Reverse Transcriptase, Bioline,
London, UK) were assembled according to the manufac-
turer’s instruction to a 10-l reaction volume. The reactions
were incubated at 65◦C for 5′, then cooled down to 50◦C be-
fore adding reverse transcriptase enzyme to each well. Sub-
sequently, the reaction temperature was decreased by 1◦C
every 1 min from 50 to 37◦C, then increased to 85◦C for
5 min to inactivate the enzyme. The cDNA products were
stored at −20◦C for later analysis.
In the KRAS G12D mutation detection assay a non-
extendable oligo that hybridizes to a region downstream of
the priming site on the RNA template was used to prevent
primer extension resulting from non-specific priming of
allele-specific RT primers to a wrong locus downstream of
the expected priming site. The sequence of this oligo was: 5′-
GAATTAGCTGTATCGTCAAGGCACTAAAAAA-3′.
Multiplex ExBP-RT assay contains, in the same reac-
tion of reverse transcription, six different mutation-specific
primers targeting all possible KRAS mutations at codon
12 and a common ExBP targeting the wild-type KRAS
transcript (please see Table 3 for sequences of primers and
probe). The concentrations of primers and probe are the
same as those of primers and probe in ‘single-plex’ ExBP-
RTassay.Due to the inclusion ofmany primers and probe in
a single reaction ofmultiplex ExBP-RT, the optimal concen-
tration of Mg2+ ion has been adjusted to 10 mM. In addti-
tion, the unbound primers and nucleotides were degraded
using 10 unit of Exonuclease I (Thermo Scientific) and
 at H
elsinki U
niversity Library on M
ay 11, 2016
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
PAGE 3 OF 11 Nucleic Acids Research, 2015, Vol. 43, No. 1 e4
Table 1. Sequences of DNA oligonucleotides used as templates to synthesize different RNA variants
Oligos Sequences with variant nucleotide in bold italic(5′-3′)
KRAS
wild-type
TAATACGACTCACTATAGGGATGACTGAATATAAACTTGTGGTAGTTGGAGCTGGTGGCGTA
GGCAAGAGTGCCTTGACGATACAGCTAATTCAGAATCA
KRAS G12D
(GGT>GAT)
TAATACGACTCACTATAGGGATGACTGAATATAAACTTGTGGTAGTTGGAGCTGATGGCGTAG
GCAAGAGTGCCTTGACGATACAGCTAATTCAGAATCA
KRAS G12A
(GGT>GCT)
TAATACGACTCACTATAGGGATGACTGAATATAAACTTGTGGTAGTTGGAGCTGCTGGCGTAG
GCAAGAGTGCCTTGACGATACAGCTAATTCAGAATCA
KRAS G12V
(GGT>CTT)
TAATACGACTCACTATAGGGATGACTGAATATAAACTTGTGGTAGTTGGAGCTGTTGGCGTAG
GCAAGAGTGCCTTGACGATACAGCTAATTCAGAATCA
KRAS G12S
(GGT>AGT)
TAATACGACTCACTATAGGGATGACTGAATATAAACTTGTGGTAGTTGGAGCTAGTGGCGTA
GGCAAGAGTGCCTTGACGATACAGCTAATTCAGAATCA
KRAS G12R
(GGT>CGT)
TAATACGACTCACTATAGGGATGACTGAATATAAACTTGTGGTAGTTGGAGCTCGTGGCGTA
GGCAAGAGTGCCTTGACGATACAGCTAATTCAGAATCA
KRAS G12C
(GGT>TGT)
TAATACGACTCACTATAGGGATGACTGAATATAAACTTGTGGTAGTTGGAGCTTGTGGCGTA
GGCAAGAGTGCCTTGACGATACAGCTAATTCAGAATCA
BRAF
wild-type
TAATACGACTCACTATAGGGTGAAGACCTCACAGTAAAAATAGGTGATTTTGGTCTAGCTACA
GTGAAATCTCGATGGAGTGGGTCCCATCAGTTTGAAC
BRAF V600E
(GTG>GAG)
TAATACGACTCACTATAGGGTGAAGACCTCACAGTAAAAATAGGTGATTTTGGTCTAGCTACA
GAGAAATCTCGATGGAGTGGGTCCCATCAGTTTGAAC
Table 2. Primer sequences used in RT-PCR assays for quantification of total KRAS and BRAF RNA transcripts
RT-PCR
assays Primers
Concen-
tration Sequences (5′-3′)
KRAS Reverse transcription primer 0.5 M AAATGATTCTGAATTAGCTGT
PCR forward primer 0.5 M GACTGAATATAAACTTGTGGTAGTTG
PCR reverse primer 0.5 M TAGCTGTATCGTCAAGGC
BRAF Reverse transcription primer 0.5 M ACTGTTCAAACTGATGGGACCCAC
PCR forward primer 0.5 M AGACCTCACAGTAAAAATAGGTGA
PCR reverse primer 0.5 M GACCCACTCCATCGAGATTTC
Table 3. Primer and probe sequences for different ExBP-RT assays
ExBP-RT assays Primers and probes Sequences (The engineering 5′-tail sequences in bold)
Concen-
trations
KRAS G12D
(GGT>GAT)
Mutation-specific
primer
GCCGATCAGACGACGACTATTATTCCATCAGCT 2 M
Wild-type-specific
blocking probe
GCCACCAGCT 4 M
KRAS G12A
(GGT>GCT)
Mutation-specific GCGCCGATCAGACGACGACTTATTCCAGCAGC 2 M
Wild-type-specific GCCACCAGCT 4 M
KRAS G12V
(GGT>CTT)
Mutation-specific
primer
GCCGATCAGACGACGACTATTATTCCAACAGCT 2 M
Wild-type-specific
blocking probe
GCCACCAGCT 4 M
KRAS G12S
(GGT>AGT)
Mutation-specific
primer
GCCGATCAGACGACGACTATTATTCCACTAGCT 2 M
Wild-type-specific
blocking probe
GCCACCAGCT 4 M
KRAS G12R
(GGT>CGT)
Mutation-specific
primer
GCCGATCAGACGACGACTATTATTCCACGAGC 2 M
Wild-type-specific
blocking probe
GCCACCAGCT 4 M
KRAS G12C
(GGT>TGT)
Mutation-specific
primer
GCCGATCAGACGACGACTATTATTCCACAAGCT 2 M
Wild-type-specific
blocking probe
GCCACCAGCT 4 M
BRAF V600E
(GTG>GAG)
Mutation-specific
primer
GCCGATCAGACGACGACTATTATTGATTTCTCTGTAG 1 M
Wild-type-specific
blocking probe
BRAF-INERT: AGATTTCACTGTAG 4 M
BRAF-PO4: AGATTTCACTGTAG- PO4 4 M
BRAF-Atail: AGATTTCACTGTAG-AAAAAA 4 M
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1 unit of Thermosensitive Alkaline Phosphatase (Thermo
Scientific) before proceeding to the quantitative PCR step.
Quantitative PCR
One microliter aliquots of each cDNA synthesis prod-
uct were used as templates in the following 10-l qPCR
reactions (SensiFASTTM SYBR No-ROX Kit, Bioline or
SensiFASTTM Probe No-ROXKit, Bioline for probe-based
detection). The PCR reactions were incubated at 95◦C for 2
min, then for 42 cycles at 95◦C for 5 s, 63◦C for 20 s and
72◦C for 10 s. In multiplex ExBP-RT, we amplified 1 l
of each cDNA synthesis product in the 10-l qPCR reac-
tions with QuantiTect SYBR PCR Kits (Qiagen) at 95◦C
for 15 min, then 45 cycles at 94◦C for 15 s and 60◦C for
45 s, in order to detect either mutant or total KRAS tran-
scripts. The primer and probe sequences for each qPCR as-
say are listed in Table 4. All qPCR assays were performed
on a LightCycler 480 II Real-Time PCR Instrument (Roche
DiagnosticsOy, Finland) using 384-well thermal block. Fol-
lowing SYBR-based qPCR, the specificity of the amplifica-
tion products was always verified by melting curve analysis.
Amplification efficiencies of qPCR assays used in this study
were determined to be 100%. All reactions were run in du-
plicate or higher replication where specified. All replicates
went through both ExBP-RT and qPCR steps.
ASB-PCR assay
Reverse transcription was performed using Tetro Reverse
Transcriptase (Bioline, London, UK) according to the
manufacturer’s instructions in a 10-l volume with 50
nM of each reverse primer. TaqMan PCR was performed
with an RT volume of 1 l in a 10-l assay with 1×
TaqMan R© Universal Master Mix II, no UNG (Applied
Biosystems, Foster City, CA), 900-nM primers, 200-nM
probe and 3600-nM blocker. Standard TaqMan thermo-
cycling conditions were used: 95◦C for 10 min, 40 cy-
cles at 95◦C for 20 s, at 60◦C for 45 s. The oligonu-
cleotides used for KRAS G12D mutation assays has
been selected from the original report (19) as follow-
ing (assay Mut2.1): Forwar mutation-specific primer: tgtg-
gtagttggagctga; Reverse primer: tgattctgaattagctgtatcgtcaa;
Blocker: ttggagctggtggcgtagg-PO4; Taqman probe: FAM−
cac + Tc + T+Tgcctacgc−BHQ1 (+N stands for LNA nu-
cleotide). Each ASB-PCR assays were run in duplicate on a
LightCycler 480 II Real-Time PCR Instrument (Roche Di-
agnostics Oy, Finland).
Data analysis
Threshold cycle (Ct) values were calculated automatically
using the default second derivative maximum method,
which is built in the LightCycler R© 480 II system (Roche Di-
agnostics Oy, Finland).
The selectivity of each ExBP-RT or other assays for
detecting mutant RNA transcripts among a surplus of
wild-type transcripts is determined by comparing products
formed in the first reaction containingmismatched template
(wild-type RNA) with those formed in the second reaction
containing the same copy number (107 copies) of matched
templates (mutant RNA). The ratio of product formed in
the first reaction normalized to product formed in the sec-
ond reaction can be determined by quantitative PCR based
on the difference in Ct values derived from two reactions
(Ctwt-mt = Ctwild-type − Ctmutant). The selectivity of each
ExBP-RT assay expressed as percentage was calculated as
2−Ct × 100%, which correspond to the lowest fraction of
mutant transcripts to be detected as a distinct signal from
the background signal derived from the wild-type template.
RESULTS
Overview of ExBP-RT strategy
We established the ExBP-RT strategy for direct transfor-
mation of RNA variants with minor differences, such as
single-base substitutions, into easily distinguishable allele-
specific products with superior selectivity using a single re-
action of reverse transcription. The reverse transcription re-
action contains a mutation-specific primer and a wild-type-
specific competitive blocking probe that is extendable (Fig-
ure 1). Both mutation-specific RT primer and the blocking
probe contain a priming sequence that is fully complemen-
tary to a specific RNA variant, but forms a mismatch with
the alternative RNA variant at the variation site. The prim-
ing sequences are designed to be short (∼10 nucleotides in
length and Tm ∼= 37–50◦C, according to DINAMelt web
server (39), which is based on the unified nearest-neighbor
parameters of oligonucleotides (40)), in order to maximize
the discrimination between perfectmatch andmismatch. By
utilizing a hot-start protocol in reverse transcription, with
a slow cool down step toward the optimal temperature for
primer annealing, the correct priming occurs at substan-
tially higher temperature and temporally prior to misprim-
ing. In particular, the mutated RNA template is selectively
primed by the mutation-specific primer during reverse tran-
scription and the resulting cDNA product is detected in
the following step based on a unique signature coupled to
the 5′ end of mutation-specific primer. Mismatch priming
of the mutation-specific primer is suppressed by neutral-
izing the wild-type template in the beginning of the reac-
tion with an extendable blocking probe. This is done by hy-
bridization and extension of the perfectly matched compet-
itive blocking probe on the wild-type template. The form-
ing cDNA binds to the wild-type RNA template with a far
greater affinity than the original blocking probe does, thus
efficiently blocking the possible site for mismatch priming
caused by mutation-specific primer, when the temperature
is decreased to a level where mispriming would be likely to
occur.
In the present report, the unique signature coupled to
the 5′ end of mutation-specific primer is a tail of unre-
lated sequence, which forms a unique downstream prim-
ing site in the mutation-specific cDNA product. This
distinction between the mutation-specific cDNA product
and blocking cDNA allows selective amplification and
detection/quantification of the mutation-specific cDNA
products by quantitative PCR, while the wild-type cDNA
that lacks the primer-binding site for the reverse PCR
primer (Figure 1B), will not be amplified.
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Table 4. Primer and probe sequences for PCR step of different ExBP-RT assays
ExBP-RT assays PCR primers
Concen-
trations Sequences (5′-3′)
KRAS G12D PCR forward primer 0.6 M AGGCCTGCTGAAAATGACTG
probe-based qPCR PCR reverse primer 0.6 M CGATCAGACGACGAC
Probe 0.4 M FAM − ATT + AT + TCCA + TCA + gC + TCC − BHQ1 (N+
stands for LNA)
KRAS mutation PCR forward primer 0.2 M GACTGAATATAAACTTGTGGTAGTTG
SYBR Green I qPCR PCR reverse primer 0.2 M CGATCAGACGACGAC
BRAF mutation PCR forward primer 0.5 M TGAAGACCTCACAGTAAA
SYBR Green I qPCR PCR reverse primer 0.5 M CGATCAGACGACGAC
KRAS mutations PCR forward primer 0.3 M CCTGCTGAAAATGACTGAA
(Multiplex ExBP-RT) PCR reverse primer 0.3 M CGATCAGACGACGAC
Total KRAS transcript PCR forward primer 0.3 M CCTGCTGAAAATGACTGAA
(Multiplex ExBP-RT) PCR reverse primer 0.3 M GCCACCAGCTCCAACTACCACAA
Wildtype RNA Mutant RNA
o
BLOCKING PROBE oMUTATION-SPECIFIC PRIMER
o
FORWARD PRIMERFORWARD PRIMER
No Amplifcation
ExBP Reverse Transcription (ExBP-RT)
o
PCR
Amplifcation
A
B
o
Figure 1. Principle of the allele-specific reverse transcription (ExBP-RT) assay. The analytical procedure includes two steps: (A, step 1) reverse transcription
with a mutation-specific RT primers and an extendable competitive blocking probe (B, step 2) selective PCR amplification and detection/quantification.
While the mutation-specific primer, which contains a nucleotide tail of unrelated sequence, generates a PCR-amplifiable cDNA product, the competitive
blocking probe without tail produces a cDNA lacking primer-binding site for the reverse PCR primer.
Detection of mutant KRAS G12R RNA in mixtures with ex-
cessive amounts of KRAS wild-type RNA
To demonstrate proof of principle, we prepared several
RNA mixtures of two in vitro-transcribed KRAS RNA
variants with different ratios. 107 copies of wild-typeKRAS
RNA were mixed with various copies of mutant KRAS
G12R RNA (108 to 103 copies), so that the ratio of mutant
versus wild-type KRASRNA ranged from 10 down to 10−4
(10, 1, 10−1, 10−2, 10−3, 10−4). The assays were performed
using the ExBP-RT strategy followed by SYBR Green I-
based quantitative PCR. Details on reaction conditions are
described in the ‘Materials and Methods’ section. Mutant
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KRAS G12R RNA was detected as a signal distinct from
the wild-type KRAS RNA at least in mixtures containing a
proportion of 1:1000 ormore ofmutantKRASG12RRNA
(Figure 2a) and the detection was linear from 1:1000 to 10:1
(Figure 2b, r2 = 0.9955, least-squares analysis). The supe-
rior selectivity of the assay has also been verified using vari-
ous copies (108 to 103 copies) of wild-typeKRASRNAonly
or mutant KRAS G12R RNA only as template (Supple-
mentary Figure S1). The amplification products have been
visualized on agarose gel 2% in order to confirm the ex-
pected size (59 bp) of amplified sequences (Supplementary
Figure S2). Omission of RNA template, mutation-specific
primer or reverse transcriptase in negative control samples
leads to complete lack of amplification.
Detection of all six possible KRASmutations at codon 12 and
the BRAF V600E mutation from RNA samples
The applicability and selectivity of the ExBP-RT strategy
for analysis of RNA variants was assessed on a panel of dif-
ferent templates andmutation types to detect all six possible
mutations at codon 12 of the KRAS gene and the BRAF
V600E mutation. The primer sequences for each assay are
listed in Table 3. The selectivity of each ExBP-RT assay was
determined by comparing products formed in the first re-
action containing mismatched template with those formed
in the second reaction containing the same copy number of
matched templates (Please see ‘Materials andMethods’ sec-
tion for more detail).
The selectivity expressed as percentage of each ExBP-RT
assay (2−Ct × 100%) was shown in Table 5. The ExBP-RT
assays was able to detect different mutant KRAS or BRAF
RNAs in the presence of 1000 to 6000-fold more excessive
background of wild-type transcripts at a selectivity ranging
from 0.017 to 0.09%.
Comparison of ExBP-RT strategy to existing technologies
In order to verify the performance of the competitive ex-
tendable blocking probe in reverse transcription, we con-
ducted a comparison to different existing approaches for
analysis of single-nucleotide RNA variants.
In the first set of experiment, BRAF V600E mutation
detection assay has been selected as a model to compare
the ExBP-RT strategy with different approaches to achieve
allele-specific priming during reverse transcription. All re-
verse transcription reactions share the same thermal pro-
gram, reagents and BRAF mutation-specific primer, but
each assay contains different blocking probes or does not
contain any blocking probe. While the ExBP-RT assay
based on an extendable competitive blocking probe gave
rise to a Ctwt-mt of 12.5 corresponding to a selectivity of
0.017% (Figure 3b), the reverse transcription without any
blocking probe results in a Ctwt-mt of only 4.4 (Figure 3a),
corresponding to a significantly lower selectivity of 5% (=
1/24.4 × 100%). When a non-extendable blocking probe
is added to the reverse transcription reaction, the result-
ing Ctwt-mt increases modestly to 5.8 (Figure 3c), which
corresponds to a selectivity of about 1.8%. Although this
selectivity is improved in comparison to that of the assay
not containing any blocking probe, it is 100× lower than
that achieved by the ExBP-RT strategy. This data clearly
shows that an extendable wild-type-specific blocking probe
outperforms the non-extendable alternative for suppression
of the mismatch priming during reverse transcription. This
subsequently leads to a superior selectivity of the ExBP-RT
assay for analysis of RNA variants.
Unlike almost all existing technologies for discrimination
of RNA variants, which utilize a DNA-based allele discrim-
ination reaction going after a ‘non-specific’ reverse tran-
scription, the selectivity of ExBP-RT is attributed directly
to allele-specific priming at the stage of reverse transcrip-
tion. In addition to the contrast in methodology, we further
compare the selectivity of the ExBP-RT assay with that of
other existing technologies in the second set of experiments.
KRAS G12D (GGT>GAT) mutation has been selected as
model, because ExBP-RT assay for detection of this RNA
variant involve the most stable primer:template mismatch
(dT:rG) (41). DifferentAS-PCRassays described in a recent
paper (19) for detection of this RNA variant was adopted
for this comparative experiment. While the ExBP-RT assay
for detection of mutant KRASG12DRNAhas a selectivity
of 0.04% as shown above, the selectivity of corresponding
optimal ASB-PCR assay (originally named Mut2.1 assay),
which employs both low-Tm discriminating PCR primer
and blocking probe, was only 0.15%.Although theCtwt-mt
value of this ASB-PCR assay was 10.1 (Supplementary Fig-
ure S3B), which is in line with the original report, this trans-
lated into a relatively low selectivity due to the low PCR
amplification efficiency of only 90% (Supplementary Fig-
ure S3A). The PCR primer with low Tm and the inhibit-
ing effect of blocking probe probably compromise the PCR
amplification efficiency in this ASB-PCR assay. When the
blocking probe is excluded from theMut2.1 assay, the selec-
tivity of consequent AS-PCR assay is greatly attenuated to
20% (2−2.3 × 100%), which is also consistent with the origi-
nal report. It is worthy noted that this Mut2.1 assay involve
the primer:templatemismatch (dA:dC), which is reasonably
unstable. When the discriminating primer was designed to
target the samemutation but on the other strand (originally
namedMut2.2 assay), the most stable primer:template mis-
match (dT:dG) is involved and the selectivity of the assay is
reported to be even worse (19).
Detection of mutant KRAS G12D RNA in FFPE samples
The PCR step of the above examples utilizes SYBR Green
I detection, but quantitative PCR using sequence-specific
probes can equally be used for detection following allele-
specific priming during reverse transcription. The follow-
ing example of utility illustrates such a probe-based assay
to detect the most common KRAS mutation type (G12D),
which accounts for ∼32.5% of all KRAS mutations (42),
from FFPE samples of colorectal cancer patients. The re-
verse transcription was performed as described with primer
and probe sequences listed in the Table 3. Identical amount
of RNA (500 ng) extracted from 11 FFPE samples was used
as a template for the allele-specific reverse transcription re-
actions. One out of 11 samples was clearly positive for the
G12D mutation (Figure 4) with a mean Ct value of 34.5
(right red curve). The positive control containing mutant
RNA (107 copies) show early amplification (left red curve),
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Figure 2. Detection of mutant KRAS G12R RNA with the ExBP-RT assay. (A) Representative qPCR amplification curves of mutant KRAS G12R RNA
serially diluted into wild-type KRAS RNA (from left to right) 10:1, 1:1, 1:10, 1:100, 1:1000 and 1:10,000 (in dark red), wild-type KRAS RNA only (in
light red) and H2O control (in green). (B) The mean Ct values (three independent assays) were plotted against the dilution of mutant RNA.
Table 5. The selectivity of ExBP-RT assays to detect different KRAS mutations at codon 12 and the BRAF V600E mutation
Mutations Ctwt-mt Selectivity (%)
KRAS G12D (GGT>GAT) 11.4 ± 0.16 0.04%
KRAS G12A (GGT>GCT) 10.5 ± 0.05 0.07%
KRAS G12V (GGT>CTT) 11.3 ± 0.09 0.04%
KRAS G12S (GGT>AGT) 10.2 ± 0.10 0.09%
KRAS G12R (GGT>CGT) 12.5 ± 0.13 0.017%
KRAS G12C (GGT>TGT) 12.2 ± 0.07 0.021%
BRAF V600E (GTG>GAG) 12.5 ± 0.05 0.017%
Figure 3. qPCR amplification curves (three replicates) derived from the same copy number of either mutant transcripts (left curves) or wild-type tran-
scripts (right curves). cDNA synthesis reactions were performed either in the absence of competitive blocking probe (A), in the presence of an extendable
competitive blocking probe (B) or in the presence of non-extendable competitive blocking probe (C).
whereas omission of RNA template or reverse transcriptase
in negative controls leads to complete lack of amplification.
All tested clinical samples were shown to contain compara-
ble amounts (0.6 – 1.8 × 105 copies/500 ng of total RNA)
of total KRASRNA (Supplementary Figure S4), which are
sufficient for the assay reproducibility (43). Agarose gel plot
also confirmed the specific band of expected size for the
tested positive sample and no specific band detected for all
the tested negative samples (Supplementary Figure S5)
Multiplex detection of different KRASmutations at codon 12
Because the ExBP-RT assay is, unlike AS-PCR, performed
during a single cycle, the common problems with forma-
tion of primer-dimers inmultiplex PCRassays is completely
avoided. Hence, designing a multiplex assay is straightfor-
ward, and simultaneous detection of several mutations in
the same reaction tube can be easily achieved. The follow-
ing example of utility describes such a multiplex ExBP-
RT assay to detect all six possible mutations within codon
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Figure 4. Detection of mutant KRAS G12D RNA in FFPE samples from
colorectal cancer patients. qPCR amplification curves of ExBP-RT assay
for detection of mutant KRAS G12D RNA in 11 FFPE samples of col-
orectal cancer patients.
12 of KRAS gene, including KRAS G12A, G12C, G12D,
G12R, G12S and G12V mutations. In contrast to ‘single-
plex’ assays mentioned above, the multiplex ExBP-RT as-
say contains, in the same reaction of reverse transcription,
six different mutation-specific primers targeting all possi-
ble KRAS mutations at codon 12 and a common ExBP
targeting the wild-type KRAS transcript (please see Table
3 for sequences of primers and probe). Identical amount
of RNA (500 ng) extracted from 44 FFPE samples of col-
orectal cancer patients has been used as templates for this
multiplex ExBP-RT assay. Positive controls containing to-
tal RNA extracted fromKRAS-mutant cell line A549 show
early amplification, and 16 out of 44 samples (36.4%) were
clearly positive for KRAS mutations at codon 12 (Figure
5). All tested mutation-positive and mutation-negative clin-
ical samples were shown to contain comparable amounts
of total KRAS RNA (Supplementary Figure S6). There
was no amplification in negative controls containing ei-
ther H2O or RNA extracted from KRAS-wild-type cell
line COLO205, and omission of RNA template or reverse
transcriptase also lead to complete lack of amplification.
The mutation rate observed in archival FFPE samples from
patients with colorectal cancer was slightly higher than
what has been reported (27.7%) in a worldwide multicen-
ter study using DNA-based mutation detection assays (44).
When analyzing another series of 87 RNA samples derived
from colonoscopy biopsies of paediatric patients with non-
malignant conditions, using the same multiplex ExBP-RT
assay, no KRAS mutations were detected at codon 12 (un-
Figure 5. Simultaneous detection of all six possible KRAS mutations at
codon 12 in FFPE samples from colorectal cancer patients. Representative
qPCR amplification curves of multiplex ExBP-RT assay for detection of
KRAS mutations at codon 12 in 44 FFPE samples of colorectal cancer
patients.
published data). In this series wild-type KRAS was readily
detected in all samples.
DISCUSSION
In this paper we show that (i) extendable competitive block-
ing probes enable allele-specific priming during reverse tran-
scription with superior selectivity, particularly when utiliz-
ing a hot start and subsequent slow cool down temper-
ature protocol; (ii) extendable wild-type-specific blocking
probes outperform non-extendable substitutes to suppress
mismatch priming during reverse transcription and (iii)
an engineered 5′-tail sequence in the mutation-specific RT
primer allows for selective PCR amplification/enrichment
of the rare variant, completely avoiding the amplification-
dependent decay of selectivity which is a well known prob-
lem related to allele-specific PCR. This ultimately results
in convenient assay for ultrasensitive detection of mutant
RNA in the presence of a 1000–10 000-fold excess of the
wild-type counterpart.
Currently, various strategies have been established for
SNP genotyping and mutation detection, usually contain-
ing the steps of target DNA amplification, allele discrimina-
tion reaction and detection/identification of allele-specific
products (29). The target amplification is performed as
the first step in almost all current strategies (2), but there
are several limitations associated with this approach. For
example, when the target amplification step is performed
prior to a separate allele discrimination reaction, such as
mini-sequencing (45–47), it is obligatory to handle post-
amplification products, which increases the risks of labora-
tory contamination. Furthermore, since both mutant and
wild-type variants are amplified with the same efficiency,
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the PCR product resulting from a rare variant will not be
enriched, and may thus be below the limit of detection,
even when the amplification is in the plateau phase. On the
other hand, when the target amplification step coincides
with the allele discrimination reaction, such as in allele-
specific PCR, the allele discriminating power decays quickly
during the course of the amplification process (29,48).
In the ExBP-RT strategy presented here, the allele dis-
crimination reaction takes place during reverse transcrip-
tion; accordingly the requirement of either performing a
separate step for allele discrimination or handling of post-
amplification products is avoided. Since the reverse tran-
scription reaction is performed during a single cycle, the re-
action time is significantly longer than the annealing and
extension times typically used in PCR. This allows for opti-
mizing the primers solely for allele discrimination, without
any restrictions or compromises that arise from concurrent
optimization to improve PCR performance. In particular,
the length of the target-specific segment of the mutation-
specific primers and blocking probe used inExBP-RT is typ-
ically only about 10 nucleotides (Tm ∼= 37–50◦C), which al-
lows for optimal discrimination between mutant and wild-
type variants in addition to assure high specificity of the
priming during reverse transcription reaction. It is worthy
noted that the Tm values of those primers and probes are
sufficiently high for our ExBP-RT assay, where the lowest
temperature of the RT protocol is 37◦C. Most importantly,
since the allele discrimination reaction takes place prior to
selective amplification of the target cDNA products, the al-
lele discriminating power achieved during reverse transcrip-
tion is unaffected by the exponential PCR amplification as
opposed to allele-specific PCR.
Non-extendable wild-type-specific blocking probes have
been widely used to reduce mispriming, and at the
same time, to improve the selectivity of most previ-
ously described competitive allele-specific PCR assays
(6,8,15,16,18,19,23,24,49,50). These probes suppress mis-
priming of the mutation-specific primers by blocking the
potential priming site upon hybridization to the wild-type
template. Our data shows, however, that the extendable
wild-type-specific blocking probes exhibit superior perfor-
mance on suppression of mispriming during reverse tran-
scription compared to non-extendable substitutes. The un-
derlying mechanism of action resulting in this difference in-
volves initiation of primer extension to form cDNA upon
hybridization of ExBP to the wild-type template. This
wild-type cDNA–RNA hybrid is much more thermostable
than hybridization of any non-extendable oligonucleotide
probe due to the significantly greater length and there-
fore, efficiently blocks the possible mispriming sites for
the mutation-specific primers as the reaction temperature
is gradually decreased. This ultimately results in effective
avoidance of mispriming to abundant wild-type RNA tem-
plate and dramatically improves the selectivity of the ExBP-
RT assay.
Unlike allele-specific PCR where stringent optimization
of PCR reaction conditions is often required to achieve suf-
ficient sensitivity (3–5,9,11,17,21,51–53), ExBP-RT assays
are relatively simple to set up without massive optimiza-
tion. In particular, all major components of the cDNA syn-
thesis reaction are within the general recommendations of
the manufacturers and a universal protocol can be applied
for detection of all mutation types on different genes. Fur-
thermore, the performance of ExBP-RT assays is likely to
be less influenced by the nature of polymorphisms and sur-
rounding sequences in comparison to AS-PCR (29). Al-
though additional evidence analyzing differentmutations in
a broader set of genes is required, our study shows that the
sensitivity of different assays varies within a narrow range
(10−3 – 10−4). Even the ExBP-RT assays for KRAS G12D
(GGT>GAT) and KRAS G12S (GGT>AGT) mutations,
which involve the most stable primer:template mismatch
(dT:rG) (41), exhibit sufficiently good selectivity of 4× 10−4
and 9× 10−4, respectively. Another important feature of the
ExBP-RT assay is the enrichment of mutations to facilitate
detection of rare mutant alleles (54), as only mutant cDNA
product comprising the engineered 5′-tail sequence is am-
plified during PCR. For the purpose of clarification, this
manuscript demonstrated ExBP-RT assays for detection of
mutant RNA variants in an excessive background of wild-
type counterparts; however, the technique can be generally
applied to detect any RNA variant in the presence of the
alternative variant regardless of their relative abundance.
As an example, the ExBP-RT assay for detection of mutant
KRASG12DRNA in the presence of another mutant vari-
ant, KRAS G12A RNA, used as a wild-type surrogate, ex-
hibited an excellent selectivity of 0.05% with a Ctwt-mt of
11.01 cycles (Supplementary Figure S7).
This technique is clearly in its infancy and our results
must be interpreted in the context of a number of poten-
tial limitations. While there are several reports of modi-
fied nucleotides that significantly improve the discrimina-
tion betweenmatched andmismatched primer:template du-
plexes (51,52,55–58), the effects of different nucleotidemod-
ifications on the selectivity of ExBP-RT assays have not
been tested in this study. Although the use of modified nu-
cleotides increases the cost of testing, studies to system-
atically investigate the benefits of different modified nu-
cleotides are warranted to boost up the selectivity of this
novel method even further for certain applications (59,60).
In addition, we have established ExBP-RT assays for detec-
tion of only seven different mutations in this study, which
does not cover all possible mutation types. Consequently,
more ExBP-RT assays need to be set up in order to draw
more reliable conclusions about the selectivity and applica-
bility of this technique in comparison with other currently
accepted strategies of mutation detection.
In conclusion, we have established a novel strategy for
analysis of RNA variant with superior selectivity using ex-
tendable competitive blocking probe in reverse transcrip-
tion (ExBP-RT). This technique is valuable for mutation
detection with ultra-high selectivity and for analysis of ex-
pressed mutations at the RNA level, which might, more
faithfully reflect the functional consequences brought upon
the cells or tissues. ExBP-RT is especially useful in situa-
tions where RNA is a mandatory starting material, such as
in epigenetic studies to analyze allele-specific gene expres-
sion, miRNA variants, exosomal RNA variants or RNA
editing and detection of mutations within the genome of
RNAviruses. The analytical procedure of ExBP-RT is rapid
and requires only moderate optimization. In combination
with qPCR using intercalating dyes or probe-based detec-
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tion, ExBP-RT is a sensitive strategy for mutation detec-
tion from RNA or for analysis of RNA variants. Although
not examined in depth in this study, it is reasonable to as-
sume that the ExBP-RT strategy might also support detec-
tion and discrimination of highly similar transcript variants
in single cells in a solution-based or in situ platform. The de-
mand for this type of analysis was highlighted in two recent
papers describing methodology for allele-specific detection
of individual mRNAs (61,62).
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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